Published in Am J Public Health on October 17, 2013
Pharmacogenetic research in partnership with American Indian and Alaska Native communities. Pharmacogenomics (2014) 0.83
Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX. Pharmacogenet Genomics (2015) 0.81
Enhancing Biospecimen Knowledge Among Health Care Providers and Representatives From Community Organizations. Health Promot Pract (2016) 0.78
Partnership with the Confederated Salish and Kootenai Tribes: Establishing an Advisory Committee for Pharmacogenetic Research. Prog Community Health Partnersh (2016) 0.75
"Getting off the Bus Closer to Your Destination": Patients' Views about Pharmacogenetic Testing. Perm J (2015) 0.75
Knowledge and attitude regarding pharmacogenetics among formerly pregnant women in the Netherlands and their interest in pharmacogenetic research. BMC Pregnancy Childbirth (2017) 0.75
A review of consent practices and perspectives for pharmacogenetic testing. Pharmacogenomics (2016) 0.75
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach. J Clin Oncol (2017) 0.75
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 32.05
Enzymatic deficiency in primaquine-sensitive erythrocytes. Science (1956) 5.39
The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol (1990) 4.89
Use of the terms race and ethnicity. Arch Pediatr Adolesc Med (2001) 3.86
Ethics. Protecting communities in biomedical research. Science (2000) 3.72
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther (2007) 3.60
Within-case and across-case approaches to qualitative data analysis. Qual Health Res (2003) 3.02
Moving towards individualized medicine with pharmacogenomics. Nature (2004) 2.99
Pharmacogenomics and individualized drug therapy. Annu Rev Med (2006) 2.95
Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc (1954) 2.65
Informed consent for biorepositories: assessing prospective participants' understanding and opinions. Cancer Epidemiol Biomarkers Prev (2008) 2.57
Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med (2007) 2.41
Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study. Am J Epidemiol (2003) 2.20
Health care professionals' perceptions of the role of pharmacogenomic data. J Manag Care Pharm (2003) 2.05
Misalliances in the Barrow Alcohol Study. Am Indian Alsk Native Ment Health Res (1989) 1.97
Attitudes about genetics in underserved, culturally diverse populations. Community Genet (2005) 1.64
Race, ethnicity, and health: can genetics explain disparities? Perspect Biol Med (2002) 1.45
Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J (2006) 1.42
Historical background of clinical trials involving women and minorities. Acad Med (1994) 1.33
Simplifying informed consent for biorepositories: stakeholder perspectives. Genet Med (2010) 1.29
The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol (2012) 1.25
Hypertension in adult American Indians. The Strong Heart Study. Hypertension (1996) 1.24
Ethical issues in identifying and recruiting participants for familial genetic research. Am J Med Genet A (2004) 1.20
Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics (2010) 1.19
HLA polymorphism in the Havasupai: evidence for balancing selection. Am J Hum Genet (1993) 1.12
Transforming genetic research practices with marginalized communities: a case for responsive justice. Hastings Cent Rep (2008) 1.12
Consumers' views of pharmacogenetics--A qualitative study. Res Social Adm Pharm (2010) 1.07
Protecting communities in pharmacogenetic and pharmacogenomic research. Pharmacogenomics J (2004) 1.04
Community-based participatory research with Native American communities: the Chronic Disease Self-Management Program. Health Promot Pract (2009) 1.01
From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system. Pharmacogenomics (2010) 1.01
Ethical considerations in clinical pharmacogenomics research. Trends Pharmacol Sci (2000) 1.00
Physical activity and incident diabetes in American Indians: the Strong Heart Study. Am J Epidemiol (2009) 0.97
Bridging the divide between genomic science and indigenous peoples. J Law Med Ethics (2010) 0.95
Community-based dialogue: engaging communities of color in the United states' genetics policy conversation. J Health Polit Policy Law (2009) 0.92
Cardiovascular disease risk factor awareness in American Indian communities: the strong heart study. Ethn Dis (2006) 0.91
Cytochrome p450 enzyme polymorphism frequency in indigenous and native american populations: a systematic review. Community Genet (2008) 0.91
Community-based participatory research and American Indian/Alaska Native nurse practitioners: a partnership to promote adolescent health. J Am Acad Nurse Pract (2011) 0.87
Race and ethnicity in the era of emerging pharmacogenomics. J Clin Pharmacol (2006) 0.87
The relevancy of community-based methods: using diet within Native American and Alaska Native adult populations as an example. Clin Transl Sci (2012) 0.86
Building partnerships in community-based participatory research: budgetary and other cost considerations. Health Promot Pract (2013) 0.85
Community-based participatory research in a large cohort study of chronic diseases among Alaska native adults. Prog Community Health Partnersh (2010) 0.83
Cancer pharmacogenomics may require both qualitative and quantitative approaches. Cell Cycle (2005) 0.83
Research ethics at Tuskegee and Willowbrook. Am J Med (1984) 0.78
Pharmacogenomics to predict drug response. Pharmacogenomics (2000) 0.77
International network of cancer genome projects. Nature (2010) 20.35
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin (2007) 12.19
Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group. Circ Cardiovasc Genet (2010) 6.74
An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA (2008) 5.25
Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA (2006) 4.87
Offering individual genetic research results: context matters. Sci Transl Med (2010) 4.51
American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin (2003) 4.43
Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet (2013) 4.06
Reconsidering the family history in primary care. J Gen Intern Med (2004) 3.50
Genomic research and wide data sharing: views of prospective participants. Genet Med (2010) 3.45
National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med (2012) 3.44
Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network. Genet Med (2012) 3.29
Glad you asked: participants' opinions of re-consent for dbGap data submission. J Empir Res Hum Res Ethics (2010) 3.29
Potential for genetics to promote public health: genetics research on smoking suggests caution about expectations. JAMA (2006) 3.20
ASHG Statement* on direct-to-consumer genetic testing in the United States. Obstet Gynecol (2007) 3.19
Newborn screening technology: proceed with caution. Pediatrics (2006) 2.54
Science and regulation. Regulating direct-to-consumer personal genome testing. Science (2010) 2.40
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med (2010) 2.40
The genomic applications in practice and prevention network. Genet Med (2009) 2.39
Implementing a Death with Dignity program at a comprehensive cancer center. N Engl J Med (2013) 2.38
Pharmacogenetic testing: not as simple as it seems. Genet Med (2008) 2.18
Genomic profiling to promote a healthy lifestyle: not ready for prime time. Nat Genet (2003) 2.11
The FDA and genomic tests--getting regulation right. N Engl J Med (2015) 2.09
Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med (2013) 2.08
Surviving surrogate decision-making: what helps and hampers the experience of making medical decisions for others. J Gen Intern Med (2007) 1.96
Next-generation sequencing in the clinic: are we ready? Nat Rev Genet (2012) 1.95
The OHRP and SUPPORT. N Engl J Med (2013) 1.78
Improvements in advance care planning in the Veterans Affairs System: results of a multifaceted intervention. Arch Intern Med (2005) 1.68
Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm (2015) 1.67
Attitudes toward genetic research review: results from a national survey of professionals involved in human subjects protection. J Empir Res Hum Res Ethics (2010) 1.59
Researcher perspectives on disclosure of incidental findings in genetic research. J Empir Res Hum Res Ethics (2010) 1.55
Beyond substituted judgment: How surrogates navigate end-of-life decision-making. J Am Geriatr Soc (2006) 1.53
Differential use of available genetic tests among primary care physicians in the United States: results of a national survey. Genet Med (2008) 1.51
Clinical decisions. Screening an asymptomatic person for genetic risk. N Engl J Med (2014) 1.51
Informed Consent in Genome-Scale Research: What Do Prospective Participants Think? AJOB Prim Res (2012) 1.50
Confronting real time ethical, legal, and social issues in the Electronic Medical Records and Genomics (eMERGE) Consortium. Genet Med (2010) 1.47
IRB perspectives on the return of individual results from genomic research. Genet Med (2012) 1.47
Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer (2008) 1.45
Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med (2011) 1.44
Current priorities for public health practice in addressing the role of human genomics in improving population health. Am J Prev Med (2011) 1.36
Taking family history seriously. Ann Intern Med (2005) 1.36
Racial disparities in alcohol use: comparison of 2 American Indian reservation populations with national data. Am J Public Health (2003) 1.35
Diverse perceptions of the informed consent process: implications for the recruitment and participation of diverse communities in the National Children's Study. Am J Community Psychol (2012) 1.28
Chinese HIV-positive patients and their healthcare providers: contrasting Confucian versus Western notions of secrecy and support. ANS Adv Nurs Sci (2007) 1.28
Trends in death associated with pediatric dental sedation and general anesthesia. Paediatr Anaesth (2013) 1.28
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med (2005) 1.27
Visiting the emergency department for dental problems: trends in utilization, 2001 to 2008. Am J Public Health (2012) 1.27
A qualitative study to identify barriers and facilitators to implementation of pilot interventions in the Veterans Health Administration (VHA) Northwest Network. Worldviews Evid Based Nurs (2004) 1.23
Challenges in operationalizing the DSM-IV clinical significance criterion. Arch Gen Psychiatry (2004) 1.22
Ethical issues in identifying and recruiting participants for familial genetic research. Am J Med Genet A (2004) 1.20
Offering aggregate results to participants in genomic research: opportunities and challenges. Genet Med (2012) 1.19
An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med (2003) 1.18
Return of incidental findings in genomic medicine: measuring what patients value--development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genet Med (2013) 1.16
Return of results: ethical and legal distinctions between research and clinical care. Am J Med Genet C Semin Med Genet (2014) 1.16
NIH State-of-the-Science Conference Statement: Role of active surveillance in the management of men with localized prostate cancer. NIH Consens State Sci Statements (2013) 1.14
Managing incidental genomic findings: legal obligations of clinicians. Genet Med (2013) 1.11
Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med (2007) 1.11
Educational needs in genetic medicine: primary care perspectives. Community Genet (2008) 1.09
dbGaP data access requests: a call for greater transparency. Sci Transl Med (2011) 1.09
Waiving informed consent in newborn screening research: balancing social value and respect. Am J Med Genet C Semin Med Genet (2008) 1.08
Breast cancer risk counseling improves women's functioning. Patient Educ Couns (2004) 1.06
Will genomics widen or help heal the schism between medicine and public health? Am J Prev Med (2007) 1.06
"You must take the medications for you and for me": family caregivers promoting HIV medication adherence in China. AIDS Patient Care STDS (2011) 1.05
Anticipating dissemination of cancer genomics in public health: a theoretical approach to psychosocial and behavioral challenges. Ann Behav Med (2007) 1.05
Genetics researchers' and IRB professionals' attitudes toward genetic research review: a comparative analysis. Genet Med (2012) 1.05
Alaska native people's perceptions, understandings, and expectations for research involving biological specimens. Int J Circumpolar Health (2012) 1.03
Does genomic risk information motivate people to change their behavior? Genome Med (2009) 1.03
Clinician-patient interactions about requests for physician-assisted suicide: a patient and family view. Arch Intern Med (2002) 1.00
Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics (2010) 0.98
Predictors of recruited melanoma families into a behavioral intervention project. Contemp Clin Trials (2011) 0.98
Primary-care physicians' access to genetic specialists: an impediment to the routine use of genomic medicine? Genet Med (2013) 0.97
Genetic exceptionalism. Too much of a good thing? Genet Med (2008) 0.97
From leaky pipeline to irrigation system: minority education through the lens of community-based participatory research. Prog Community Health Partnersh (2012) 0.97
Family history assessment to detect increased risk for colorectal cancer: conceptual considerations and a preliminary economic analysis. Cancer Epidemiol Biomarkers Prev (2005) 0.97
Genetic information: Special or not? Responses from focus groups with members of a health maintenance organization. Am J Med Genet A (2007) 0.96
Implementation outcomes of a multiinstitutional web-based ethical, legal, and social implications genetics curriculum for primary care residents in three specialties. Genet Med (2011) 0.96
Motivations for physician-assisted suicide. J Gen Intern Med (2005) 0.95
Effects of individual and family functioning on interest in genetic testing. Community Genet (2004) 0.94
Attitudes toward antiretroviral therapy and complementary and alternative medicine in Chinese patients infected with HIV. J Assoc Nurses AIDS Care (2009) 0.94
Effects of web-based intervention on risk reduction behaviors in melanoma survivors. J Cancer Surviv (2014) 0.94
Beneficence, clinical urgency, and the return of individual research results to relatives. Am J Bioeth (2012) 0.93
The rules remain the same for genomic medicine: the case against "reverse genetic exceptionalism". Genet Med (2010) 0.93
Why don't patients enroll in hospice? Can we do anything about it? J Gen Intern Med (2010) 0.91
Cytochrome p450 enzyme polymorphism frequency in indigenous and native american populations: a systematic review. Community Genet (2008) 0.91
Health system implications of direct-to-consumer personal genome testing. Public Health Genomics (2010) 0.90
Population description and its role in the interpretation of genetic association. Hum Genet (2010) 0.90
Examining palliative care team involvement in automatic consultations for children on extracorporeal life support in the pediatric intensive care unit. J Palliat Med (2013) 0.89
Will knowledge of gene-based colorectal cancer disease risk influence quality of life and screening behavior? Findings from a population-based study. Public Health Genomics (2009) 0.88
Mental health and the city: intra-urban mobility among individuals with schizophrenia. Health Place (2006) 0.88
Maternal perspectives on the return of genetic results: context matters. Am J Med Genet A (2012) 0.88
Breast cancer risk communication: assessment of primary care physicians by standardized patients. Genet Med (2009) 0.88
After the fall from grace: negotiation of new identities among HIV-positive women in Peru. Cult Health Sex (2008) 0.87
Incorporating principles and practical wisdom in research ethics education: a preliminary study. Acad Med (2007) 0.87
Engaging stakeholders to develop a depression management decision support tool in a tribal health system. Qual Life Res (2014) 0.86
Patient and provider perspectives on using telemedicine for chronic disease management among Native Hawaiian and Alaska Native people. Int J Circumpolar Health (2013) 0.86